Quinacrine enhances venous thrombus resolution through myeloid p53-dependent and MMP-2-independent manners. (A) Thrombus weights of vehicle- and quinacrine-treated CD1 mice at (A) day 4 (n = 6-7 per group) and (B) day 12 (n = 5-6 per group), after vena cava ligation. (C) Thrombus weights of Mp53^−/− mice at 12 days after vena cava ligation are unaffected after pretreatment with quinacrine (n = 6) or PFT (n = 5) compared with vehicle (n = 5). (D) Representative gel images of intrathrombotic MMP-2 and MMP-9 activities measured by gelatin gel zymography in day 8 venous thrombus samples from CD1 mice pretreated with vehicle (n = 4) or quinacrine (n = 4). Gel images were subjected to semiquantitative analysis as described in “Methods.” All values represent the mean ± SEM. (E) Thrombus weights of Mmp2^−/− mice at 12 days after vena cava ligation following pretreatment with vehicle or quinacrine (n = 5 vehicle and 5 quinacrine).